Literature DB >> 24799580

Decomposing growth in spending finds annual cost of treatment contributed most to spending growth, 1980-2006.

Martha Starr, Laura Dominiak, Ana Aizcorbe.   

Abstract

Researchers have disagreed about factors driving up health care spending since the 1980s. One camp, led by Kenneth Thorpe, identifies rising numbers of people being treated for chronic diseases as a major factor. Charles Roehrig and David Rousseau reach the opposite conclusion: that three-quarters of growth in average spending reflects the rising costs of treating given diseases. We reexamined sources of spending growth using data from four nationally representative surveys. We found that rising costs of treatment accounted for 70 percent of growth in real average health care spending from 1980 to 2006. The contribution of shares of the population treated for given diseases increased in 1997-2006, but even then it accounted for only one-third of spending growth. We highlight the fact that Thorpe's inclusion of population growth as part of disease prevalence explains the appreciable difference in results. An important policy implication is that programs to better manage chronic diseases may only modestly reduce average spending growth.

Entities:  

Keywords:  Cost of Health Care; Financing Health Care; Health Economics; Health Spending; Medical technology

Mesh:

Year:  2014        PMID: 24799580     DOI: 10.1377/hlthaff.2013.0656

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  14 in total

1.  Decomposing changes in the growth of U.S. prescription drug use and expenditures, 1999-2016.

Authors:  Thomas M Selden; Salam Abdus; G Edward Miller
Journal:  Health Serv Res       Date:  2019-05-09       Impact factor: 3.402

Review 2.  Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States.

Authors:  Abe Dunn; Scott D Grosse; Samuel H Zuvekas
Journal:  Health Serv Res       Date:  2016-11-21       Impact factor: 3.402

3.  Advanced Imaging Reduces Cost Compared to Standard of Care in Emergency Department of Triage of Acute Chest Pain.

Authors:  Pamela S Noack; Jhanna A Moore; Michael Poon
Journal:  Health Serv Res       Date:  2017-11-13       Impact factor: 3.402

4.  Guidelines for Measuring Disease Episodes: An Analysis of the Effects on the Components of Expenditure Growth.

Authors:  Abe Dunn; Eli Liebman; Lindsey Rittmueller; Adam Hale Shapiro
Journal:  Health Serv Res       Date:  2016-05-03       Impact factor: 3.402

5.  Understanding Trends in Medicare Spending, 2007-2014.

Authors:  Laura M Keohane; Robert J Gambrel; Salama S Freed; David Stevenson; Melinda B Buntin
Journal:  Health Serv Res       Date:  2018-03-06       Impact factor: 3.402

6.  Factors Associated With Increases in US Health Care Spending, 1996-2013.

Authors:  Joseph L Dieleman; Ellen Squires; Anthony L Bui; Madeline Campbell; Abigail Chapin; Hannah Hamavid; Cody Horst; Zhiyin Li; Taylor Matyasz; Alex Reynolds; Nafis Sadat; Matthew T Schneider; Christopher J L Murray
Journal:  JAMA       Date:  2017-11-07       Impact factor: 56.272

7.  Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.

Authors:  Natalie McCormick; Zachary S Wallace; Chana A Sacks; John Hsu; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2020-01-06       Impact factor: 10.995

8.  Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005-2007 and 2015-2017.

Authors:  Xilin Zhou; Sundar S Shrestha; Hui Shao; Ping Zhang
Journal:  Diabetes Care       Date:  2020-07-31       Impact factor: 19.112

9.  Health Care Spending on Diabetes in the U.S., 1996-2013.

Authors:  Ellen Squires; Herbert Duber; Madeline Campbell; Jackie Cao; Abigail Chapin; Cody Horst; Zhiyin Li; Taylor Matyasz; Alex Reynolds; Irl B Hirsch; Joseph L Dieleman
Journal:  Diabetes Care       Date:  2018-05-10       Impact factor: 19.112

10.  Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation.

Authors:  Padraig Dixon; George Davey Smith; Stephanie von Hinke; Neil M Davies; William Hollingworth
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.